Reblozyl
New Therapy for MDS-Related Anemia More Effective Than Standard Epoetin Alfa
In a phase 3 trial, Reblozyl was more effective than epoetin alfa for achieving independence from red blood cell ...
JANUARY 17, 2024
Beta Thalassemia Requires Specialized Management for Patients, Payors and Pharmacists
Patients with beta thalassemia have a high disease burden that requires specialized management. Although there are ...
MARCH 23, 2023
FDA Approves Reblozyl to Treat Anemia in Some Patients With MDS
The FDA approved luspatercept-aamt (Reblozyl, Celgene) for the treatment of anemia in adults with very low- to ...
APRIL 10, 2020
Load more